Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 3/20 | 0.60 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.56 |
| ▸ | PRKACA | P17612 | 2/20 | 0.56 |
| ▸ | MARS1 | P56192 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.54 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.54 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.54 |
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | FBP1 | P09467 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.54 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10587742 | 0.92 | AHCY (0.61) | AHCYHSP90B1PRKACAMARS1ADORA1 | |
| SCHEMBL1066705 | 0.91 | PRKACA (0.66) | AHCYHSP90B1PRKACAMARS1ADORA1 | |
| SCHEMBL15293701 | 0.90 | AHCY (0.51) | AHCYHSP90B1PRKACAMARS1ADORA1 | |
| SCHEMBL15293700 | 0.90 | AHCY (0.51) | AHCYHSP90B1PRKACAMARS1ADORA1 | |
| SCHEMBL22875576 | 0.89 | EHMT1 (0.60) | AHCYHSP90B1PRKACA | |
| SCHEMBL22875787 | 0.89 | EHMT1 (0.60) | AHCYHSP90B1PRKACA | |
| SCHEMBL11686718 | 0.88 | AHCY (0.62) | AHCYHSP90B1PRKACAMARS1ADORA1 | |
| SCHEMBL23982338 | 0.88 | AHCY (0.51) | AHCYHSP90B1PRKACAMARS1ADORA1 | |
| SCHEMBL15297002 | 0.87 | AHCY (0.49) | AHCYHSP90B1PRKACAMARS1ADORA1 | |
| SCHEMBL15293696 | 0.86 | AHCY (0.50) | AHCYPRKACAMARS1ADORA1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379536-A4 | BUILDING BLOCKS FOR THE SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20040096947-A1 | Building blocks for the solution phase synthesis of oligonucleotides | SANGHVI YOGESH S (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1379536-A1 | BUILDING BLOCKS FOR THE SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | ISIS Pharmaceuticals, Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6677120-B2 | PREFERENTIAL DEPROTECTION OF A 3',5'-DI-O- LEVULINYL NUCLEOSIDE; OBTAIN 3',5'-DI-O-LEVULINYL NUCLEOSIDE, INCUBATE WITH LIPASE, RECOVER 3'-O-LEVULINYL AND 5'-O-LEVULINYL NUCLEOSIDE | ISIS PHARMACEUTICALS, INC. | 2004-01-13 | — | — | US | disclosed |
| WO-2002079215-A1 | BUILDING BLOCKS FOR THE SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020142307-A1 | Building blocks for the solution phase synthesis of oligonucleotides | IONIS PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040096947-A1 | Building blocks for the solution phase synthesis of oligonucleotides | RNGTT, TYMS, POLB | AHCY 561/4885HSP90B1 4676/4885PRKACA 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.